New research indicates that various features assessed through imaging tests can reveal an individual’s risk of developing meniscus tears, which is one of the most common knee injuries.
First Treatment Approved for Genetic Clotting Disorder
The FDA approved a recombinant ADAMTS13 protein product (Adzynma) as a prophylactic or on-demand enzyme replacement therapy for patients with congenital thrombotic thrombocytopenic purpura (cTTP).
November 11, 2023